Navigate Titan Pharmaceuticals, Inc.
Home
About
Overview
Management Team
Board of Directors
Careers
News
Overview
Press Releases
Events
Presentations
In the News
Media Resources
Investors
Overview
News / Events
Company Information
SEC Filings
Corporate Governance
Contact
Search
All SEC Filings
Home
Investors
SEC Filings
All SEC Filings
Investors
Navigate Investors
Overview
News / Events
Company Information
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Email Alerts
Tear Sheet
Contacts
RSS News Feed
All SEC Filings
Filter Filings:
View All
10-12G
10-12G/A
10-K
10-K/A
10-K405
10-Q
10-Q/A
10KSB40
10QSB
15-12B
15-12G
25
25-NSE
3
3/A
4
4/A
424B2
424B3
424B4
424B5
425
8-A12B
8-A12B/A
8-A12G
8-K
8-K/A
ARS
AW
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DEFM14A
DEFN14A
DEFR14A
DFAN14A
EFFECT
FWP
NT 10-Q
POS AM
PRE 14A
PREN14A
PRRN14A
REGDEX
RW
S-1
S-1/A
S-1MEF
S-3
S-3/A
S-8
S-8 POS
SB-2
SB-2/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
UPLOAD
Date
Form
Description
Docs
XBRL
Pages
10/09/25
POS AM
Post-effective amendment to a registration statement that is not immediately effective upon filing
2
10/08/25
4
Statement of changes in beneficial ownership of securities
1
10/02/25
25-NSE
Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Related Documents
EX-99.25
2
10/01/25
8-K
Current report
2
08/26/25
8-K
Current report
2
08/22/25
DEFA14A
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11
08/14/25
DEFA14A
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
2
08/14/25
10-Q
Quarterly report [Sections 13 or 15(d)]
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
19
07/22/25
DEFA14A
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
3
07/22/25
DEFM14A
Definitive proxy statement relating to merger or acquisition
253
<< Previous
1
2
3
4
5
6
7
8
9
10
...105
Next >>